Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline and expert task force recommendation statement.
PubMed 35997723 · doi:10.1001/jama.2022.13044
What was done
The US Preventive Services Task Force (USPSTF) commissioned an updated systematic review evaluating the benefits and harms of statins for reducing cardiovascular disease (CVD) morbidity, CVD mortality, and all-cause mortality. The target population was community-dwelling adults aged 40 years or older without known CVD or related symptoms.
What was found
The abstract reports no numerical effect sizes or risk ratios. Based on qualitative certainty assessments, statin initiation has a moderate net benefit for adults aged 40 to 75 years with 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a 10-year CVD risk of 10% or greater (Grade B recommendation). For individuals aged 40 to 75 with 1 or more risk factors and a 10-year CVD risk of 7.5% to less than 10%, statins provide a small net benefit (Grade C recommendation, suggesting selective offering). Evidence was insufficient to determine the balance of benefits and harms in adults aged 76 years or older (I statement).
Why it matters
This guideline provides formal clinical recommendations for statin initiation in primary prevention, stratifying decision thresholds by estimated 10-year baseline cardiovascular risk.
Limits
The abstract reports no quantitative estimates of benefit (such as absolute risk reductions or numbers needed to treat) or specific adverse event rates. Evidence remains explicitly insufficient for individuals aged 76 and older, and recommendations rely on 10-year CVD risk estimation tools that may have calibration inaccuracies across diverse populations.
Cited by
- supports Cardiovascular disease is the leading cause of death in the United States.